Edition:
India

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

19.99USD
17 Aug 2018
Change (% chg)

$-1.29 (-6.06%)
Prev Close
$21.28
Open
$21.34
Day's High
$21.60
Day's Low
$19.96
Volume
307,358
Avg. Vol
241,474
52-wk High
$41.14
52-wk Low
$19.96

Chart for

About

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosi... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $1,686.22
Shares Outstanding(Mil.): 43.50
Dividend: --
Yield (%): --

Financials

BRIEF-Radius Health Reports Q1 Loss Per Share Of $1.37

* RADIUS HEALTH REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

10 May 2018

BRIEF-Radius Health Initiates Phase 3 Trial Of Abaloparatide Injection For Male Osteoporosis

* RADIUS HEALTH INITIATES PHASE 3 CLINICAL TRIAL OF ABALOPARATIDE INJECTION FOR THE TREATMENT OF MALE OSTEOPOROSIS Source text for Eikon: Further company coverage:

31 Mar 2018

BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC

* RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC

22 Mar 2018

BRIEF-Radius Health Reports Q4 Loss Per Share $1.59

* RADIUS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

02 Mar 2018

Earnings vs. Estimates